## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Paul K. Smith	)
Serial No.:	Not Yet Assigned	<pre>) Attorney Docket: ) 7587/91197</pre>
Filed:	December 19, 2003	) PKS-102.0 Div. I )
	TIVATED POLYETHYLENE GLYCOL	) Examiner: ) Not Yet Assigned

## INFORMATION DISCLOSURE STATEMENT

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Sir:

Pursuant to 37 C.F.R. §1.97, a list of documents that may be material to the examination of this application is provided on the attached Form PTO-SB/08. Listed Documents A1 to A25 and B1 to B2 are U.S. and foreign patents, and/or pertinent articles that may be relevant to the examination of the present application.

Documents A1 to A25 listed on the attached Form PTO-SB/08 were cited and supplied to the Patent and Trademark Office in the parental application, Serial No. 10/105,644, filed March 25, 2002, the benefit of which filing date is claimed herein. Pursuant to 37 C.F.R. 1.98(d), it is understood that only a list of art is required inasmuch as the art has been provided and discussed previously.

Information Disclosure Statement December 19, 2003

Documents for which the supplied date of publication lists the year of publication without the month were published sufficiently earlier than the effective U.S. filing date and any foreign priority date, so that the particular month of publication is not in issue. Pursuant to §609 of the MPEP, it is understood that the month of publication is not required when the particular month of publication is not in issue.

No inferences should be drawn that the attached list represents a comprehensive investigation, or that any material disclosed is equivalent to the subject invention. In addition, none of the documents that have publication dates prior to the priority date of the above application anticipate the invention in this application.

The cited documents disclose numerous specific features. There has been no attempt to list each and every feature disclosed by each document. The Examiner is requested to review the documents and determine the extent of the materiality of the document disclosures with respect to the present invention.

The discussion of any art and the citation of any document herein is not to be construed as an admission that the art or document disclosure is necessarily within the invention field of endeavor, that the art or document disclosure is necessarily prior in time to a particular date which may be relevant to the instant patent application, and/or that the art

Information Disclosure Statement December 19, 2003

or document disclosure is otherwise necessarily prior art as defined by the patent law with respect to the instant invention and application.

Also, there is reserved the right to later set forth how the instant invention is distinguished over the disclosure of any document or other art, including the disclosures of the art and documents recited herein, that may be cited by the Examiner in rejecting a claim in the instant patent application.

The recitation herein of the art and documents is not to be construed as an assertion that more pertinent art could not possibly be in existence.

No further fee or petition is believed to be necessary. However, should any fee be needed, please charge our Deposit Account No. 23-0920, and deem this paper to be the required petition.

Respectfully submitted,

Shannon L. Nebolaky, Reg. No. 41

Welsh & Katz, Ltd. 22nd Floor 120 South Riverside Plaza Chicago, Illinois 60606 312/655-1500

I hereby certify that this paper is being deposited with the United States Postal Service as Express Mail in an envelope addressed to: Mail Stop\_\_\_\_\_\_\_, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date.

Dec. 19.200

Express Mail Label No. EL 995662436 4S

PTO/SB/08A & PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/24/2001 W	&K Substitute for Form PTO-SE	B/08A, wh	ich is a US PTO	Complete if Known			
Substitute for form 1449A/PTO and 1449B/PTO				Application Number	Not Yet Assigned		
INFO	RMATION D	ISC	LOSURE	Filing Date	December 19, 2003		
STATEMENT BY APPLICANT				First Named Inventor	Paul K. Smith		
			LICANI	Art Unit			
(use as many sheets as necessary)			necessary)	Examiner Name			
Sheet	1	of	2	Attorney Docket Number	7587/91197 (PKS 102.0 Div. I)		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	A1	US-5,585,484	12/17/96	Acharya et al.			
	A2	US-5,750,725	5/12/98	Acharya et al.			
	A3	US-6,017,943	1/25/00	Acharya et al.			
•	A4	US-4,356,170	10/26/82	Jennings et al.			
	A5	US-4,220,717	9/2/80	Kuo			
	A6	US-6,312,916	11/6/2001	Kopetzki, et al.			
	A7	US-5,880,255	3/9/99	Delgado, et al.			
	A8	US-5,349,052	9/20/94	Delgado, et al			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6		
	A9	EP 0 157 899-B1	10/16/86	American Cyanamid Company				
	A10	EP 0 126 043 A1	11/21/84	Svenska Sockerfabrics	***************************************	-		
***************************************	A11	EP-0157 899 A2	10/16/85	American Cyanamid Company	COLUMN TO THE			
	A12	EP-0126 043 B1	11/21/84	Andersson, et al.				

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sub>6</sub>
	A13	Jerry E. SQUIRES, "Artificial Blood", Science, 295:1002, 1004-1005 (February 8, 2002)	
	A14	J. Milton HARRIS, ed., Poly(ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications: Topics in Applied Chemistry, Plenum Press (New York: 1992), pp. 1-379	
NAME OF THE OWNER	A15	J. Milton HARRIS and Samuel ZALIPSKY, eds., Poly(ethylene Glycol) Chemistry and Biological Applications: ACS SYMPOSIUM SERIES 680, American Chemical Society Publishing (Washington, D.C.: 1997), p. 1-341	
	A16	SHEARWATER CORPORATION, Catalog 2001: Polyethylene Glycol and Derivatives for Biomedical Applications, Huntsville, AL 35801, (pp. 1-17)	
	A17	Susan BUDAVARI, et al., eds., Merck Index, 11th Ed., Merck & Co., Inc. (Rahway, N.J.: 1989), p. 7275, Compound No. 7268	
Examir Signati		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional), <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3), <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A & PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to reso

	&K Substitute for Form PTO-5		ich is a US PTO	Complete if Known		
Substitute for form 1449A/PTO and 1449B/PTO				Application Number	Not Yet Assigned	
INFO	RMATION D	ISC	LOSURE	Filing Date	December 19, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Paul K. Smith	
JIAI	STATEMENT BY APPLICANT			Art Unit		
(use as many sheets as necessary)			necessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	7587/91197 (PKS 102.0 Div. I)	

A18	PORRO et al., "Specific Antibodies to Diphtheria Toxin and Type 6A Pneumococcal Capsular Polysaccharide Induced By A Model of Semi-Synthetic Glycoconjugate Antigen" (1985) Mol. Immunol., 22:907-919	
A19	ANDERSON et al., "Vaccines Consisting of Periodate-Cleaved Oligosaccharides from the Capsule of Haemophilus Influenze Type b Coupled to a Protein Carrier: Structural and Temporal Requirements for Priming in the Human Infant," (1986) J. Immunol., 137:1181-1186	
A20	WITTE et al., "Enzymatic Glycoprotein Synthesis: Preparation of Ribonuclease Glycoforms via Enzymatic Glycopeptide Condensation and Glycosylation," (1997) J. Am. Chem. Soc., 119:2114-2118	
A21	Michael E. ANNUNZIATO, et al., "p-Maleimidophenyl Isocyanate: A Novel Heterobifunctional Linker for Hydroxyl to Thiol Coupling," Bioconjugate Chem., 4:212-218 (1993)	
A22	ALDRICH, Aldrich: Catalog Handbook of Fine Chemicals, (1998-1999), p. 83, Product No. 18,627-9	
A23	Belur N. MANJULA, et al., "Cys-93-\( \text{B}\) Succinimidophenyl Polyethylene Glycol 2600  Hemoglobin A: (Intramolecular Cross-Bridging of Hemoglobin Outside the Central Cavity,"  J. Biol. Chem., 275(8):5527-5534 (2000)	
A24	POLYMASC PHARMACEUTICALS, PLC, "Attachment of Polyethylene Glycol (PEG)," taken from www.polymasc.com/PEG/htm (February 8, 2000)	
A25	POLYMASC PHARMACEUTICALS, PLC, "Biological Optimisation and Its Importance," taken from www.polymasc.com/PEGii.htm (February 8, 2000)	
B1	KRICHELDORF, et al. Chemical Abstracts, 95:25583, 1981	
B2	VISWANATHAN, et al., Indian Journal of Chemistry, 20B, 308-310, 1981	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.